Why the study?
Patients with Marfan syndrome have an increased risk of aortic complications and subtle cardiomyopathy, prompting an analysis of metabolic pathways to identify biomarker patterns for monitoring cardiovascular risk and myocardial function deterioration.
Are there differences in amino acid and phospholipid metabolism between patients with Marfan syndrome and healthy controls that indicate subtle cardiomyopathy?
Are there differences in amino acid and phospholipid metabolism between patients with Marfan syndrome and healthy controls that indicate subtle cardiomyopathy?
Alterations in serum levels of specific amino acids and phospholipids link Marfan syndrome pathophysiology with inflammation, oxidative stress, and incipient cardiomyopathy.
Metabolite shifts may flag early cardiomyopathy in Marfan syndrome; hypothesis-generating for prospective validation and interventions.
Patients with Marfan syndrome (MFS) have an increased risk of aortic aneurysm formation, dissection and development of a subtle cardiomyopathy. We analyzed amino acid and lipid metabolic pathways in MFS patients, seeking biomarker patterns as potential monitoring tools of cardiovascular risk with deterioration of myocardial function. We assessed myocardial function in 24 adult MFS patients and compared traditional laboratory values and mass spectrometry-based amino acid, phospholipid and acylcarnitine metabolomes in patients with those in healthy controls. Analytes for which values differed between patients and controls were subjected to regression analysis. A high proportion of patients had signs of impaired diastolic function and elevated serum levels of NT-proBNP. Patients had lower serum levels of taurine, histidine and PCaeC42:3 than controls. The evidence of diastolic dysfunction, aortic root dimensions and history of aortic root surgery correlated with NT-proBNP and taurine levels. Alterations in serum levels of metabolism derived analytes link MFS pathophysiology with inflammation, oxidative stress and incipient cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Bartenbach et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: